Growth Policies and Experiences among Asian Countries
Japan was the first Asian country to become a modern developed country and has experienced various successes and failures, all of which can serve as valuable references for growing Asian countries. This group conducts research on what emerging Asian countries, as Japan’s important economic cooperation partners, can learn from Japan’s economic development process and related policies, and make policy recommendations based on the research findings.
Moreover, the present era is no longer one in which institutional reforms can be learned only from western countries. In this area, this group conducts research on what Japan can learn from the dynamic economic growth and related policies of Asian countries that grew remarkably in recent years, making policy recommendations based on the research results.
For the past several years, I have mainly studied Taiwan’s startup ecosystem, especially focusing on accelerators, and my research in 2023 will continue this. Usually, accelerator research looks only at this as a startup development program and mainly analyzes its contents (for example, details of entrepreneur education programs and mentoring methods and their effects). This research considers accelerators not as mere training programs, but as a kind of (strategically acting) company that has its own mission, goals, concepts, different positioning and organizational capabilities, builds its own competitive advantage, and aims to achieve its mission and goals. The startup development program is also positioned in the overall picture of such a strategy, and its contents are defined by the strategy.
Accelerators that appear similar at first glance are quite different in their strategies if you look at them in detail. Broadly speaking, even if accelerators’ role is to support the launch of startups and contribute to the development of the ecosystem through the formation of startup communities, the methods are unique and quite different among accelerators. By observing these differences and the actual situation of strategy formation and implementation in detail, it is expected to lead to an understanding of the formation and development of a mechanism in which an ecosystem function as a “system”
Improving access to medicines is essential for enhancing national health and reducing health inequalities. The effective operation of drug pricing and insurance systems is key to achieving this goal. Governments worldwide are now applying Health Technology Assessment (HTA) to inform drug pricing and public health insurance coverage.
Although HTA has increased in importance in policy decisions, it typically focuses only on individual drugs and does not assess overall access to drugs. In addition, due to lack of data, existing studies have not evaluated the efficiency of drug pricing as well insurance policies in terms of drug accessibility.
The purpose of this study is to assess the efficiency of the drug pricing and insurance system by quantifying the impact of drug list changes on drug access.